SS-31 Peptide: What Research Shows About Benefits, Dosage, and Safety

SS-31 (also studied and sold under the names elamipretide, MTP-131, and Bendavia) is a synthetic four-amino-acid peptide that concentrates in the inner mitochondrial membrane and is researched for its effects on cellular energy production. SS-31 is not FDA-approved for any human indication in the United States, and no regulatory agency has cleared it as a prescription drug. Most of what is known comes from company-sponsored clinical trials in rare mitochondrial diseases and heart failure, plus animal research.

What SS-31 Is and How It Works

SS-31 is a tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, which places it in the family of aromatic-cationic peptides. Its structure allows it to cross cell membranes and bind cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane.

That binding matters because cardiolipin is damaged early in many forms of cellular stress. When cardiolipin oxidizes, mitochondrial cristae lose their shape and electron transport slows down. SS-31 appears to stabilize cardiolipin and reduce the leakage of reactive oxygen species.

• Target: inner mitochondrial membrane and cardiolipin
• Primary proposed effect: more efficient ATP production and less oxidative damage
• Half-life: short, which is why trial protocols use daily or continuous dosing
• Route in trials: subcutaneous injection or intravenous infusion

What Research Says About Benefits and Limits

The most credible ss-31 peptide benefits reported in the literature relate to mitochondrial efficiency, not muscle growth or fat loss. Trials have measured walking distance, cardiac function, and vision endpoints rather than gym performance.

• Barth syndrome: phase 2/3 data showed improvement on some functional measures, but the FDA declined approval in 2024 and requested more evidence.
• Primary mitochondrial myopathy: phase 3 results on the six-minute walk test were mixed.
• Heart failure: a large phase 3 trial did not meet its primary endpoint.
• Animal models: protective effects have been reported in kidney injury, stroke, and ischemia-reperfusion studies.

Elamipretide has not met its primary endpoint in a large heart failure trial, so claims that SS-31 reverses human heart disease are not supported by current evidence. Positive animal results do not automatically translate into human benefit.

Reported Dosing in Trials and Community Use

There is no established ss-31 peptide dosage for healthy adults, because no regulator has approved the compound for that population. The figures below come from published trials or from self-reported community use, and they are not a recommendation.

Setting	Route	Reported dose	Frequency
Barth syndrome trials	Subcutaneous	40 mg	Once daily
Heart failure trials	IV infusion	4 mg per hour	4-hour infusion
Mitochondrial myopathy trials	Subcutaneous	40 mg	Once daily
Community / research peptide use	Subcutaneous	1–10 mg (often 5 mg)	Once daily, self-reported

Because SS-31 clears quickly from plasma, most protocols favor once-daily or continuous dosing rather than weekly injections. Anyone considering use should talk with a licensed healthcare professional first, since dosing from forum posts carries real risk.

Side Effects and Safety Signals

In clinical trials, the most common ss-31 peptide side effects were mild and related to the injection itself. Serious events were rare, but the total number of treated patients remains small.

• Injection site pain, redness, or swelling (reported most often)
• Headache and dizziness
• Nausea and fatigue
• Transient blood pressure changes during IV infusion

SS-31 peptide side effects reported in trials have generally been mild, but no long-term safety data exists in healthy people and there is no data on use during pregnancy or breastfeeding. Research chemicals sold online are unregulated, so purity and actual content can vary between vendors and batches.

SS-31 Compared With Other Mitochondrial and Recovery Peptides

Peptide	Main mechanism studied	Common research route	FDA status
SS-31 (elamipretide)	Cardiolipin binding, mitochondrial antioxidant	Subcutaneous or IV	Not approved
MOTS-c	AMPK activation, metabolic regulation	Subcutaneous	Not approved
BPC-157	Angiogenesis and tissue repair (animal data)	Subcutaneous or oral	Not approved
TB-500 (thymosin beta-4 fragment)	Cell migration, actin regulation	Subcutaneous	Not approved

A commonly discussed ss-31 and mots-c protocol pairs a mitochondrial membrane peptide with a metabolic peptide, based on the theory that energy production and fuel handling work together. No controlled human trial has tested an SS-31 and MOTS-c combination, and stacking research peptides increases the chance of unknown interactions.

In ss-31 peptide bodybuilding discussions, users often describe better endurance and faster recovery between sessions. Those reports are anecdotal. SS-31 is not an anabolic agent, and it does not build muscle the way testosterone or growth hormone secretagogues do.

Legal Status and What to Check Before Buying

SS-31 is sold online as a "research chemical" labeled for laboratory use only, which is how vendors sidestep FDA drug regulations. Buying it for personal injection is a legal and safety gray area, and the product you receive may not match the label.

• Look for a third-party certificate of analysis that includes purity and mass spectrometry data.
• Check whether the vendor publishes the testing lab's name and batch numbers.
• Be skeptical of claims that a peptide cures fatigue, heart disease, or aging.

Anyone with a diagnosed mitochondrial condition should ask a physician about clinical trials or approved alternatives instead of self-treating with an unapproved research peptide.

COMMON QUESTIONS

Frequently Asked Questions

What is the SS-31 peptide used for?

SS-31 (elamipretide) has been studied in clinical trials for Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration. All of these uses remain investigational, and the FDA declined to approve elamipretide for Barth syndrome in 2024. It is not approved for general energy, anti-aging, or athletic use.

What is a typical SS-31 peptide dosage?

There is no established SS-31 dosage for healthy adults. In published trials, participants received 40 mg subcutaneously once daily for mitochondrial disease, or a 4 mg per hour intravenous infusion in heart failure studies. Community users often report 1–10 mg subcutaneously per day, but those numbers are anecdotal and not medically endorsed.

Is SS-31 approved by the FDA?

No. SS-31, also called elamipretide, has not been approved by the FDA for any human indication as of 2025. It is legally sold only as a research chemical for laboratory use, which means purity, sterility, and dosing are not verified by any regulator. Talk to a healthcare professional before using any unapproved peptide.